Trial intelligence / Profile preview

Phase II taletrectinib study in ROS1-positive advanced or metastatic NSCLC and other solid tumors

CTR20232541Phase 2Active

Sponsor

AnHeart Therapeutics

Start

Jun 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1